Combining Dalantercept and Axitinib for Advanced Kidney Cancer
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study.
Clinical Pearls
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study. The study compareddalantercept plus axitinib with placebo plus axitinib for patients with advanced clear cell renal cell carcinoma.
- Dose-determining toxicities for dalantercept were fluid retention and anemia.
- No additive toxicity was observed. The combination was well tolerated, even at the highest dose levels.
- Median PFS was approximately 8 months for the entire study population.
- Median PFS has not yet been reached among patients receiving the dose chosen for part II of the study.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
